StockNews.AI
NVNO
StockNews.AI
13 days

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

1. VenoValve may reduce healthcare costs by $5.9 billion annually. 2. Clinical data supports better health outcomes for severe CVI patients.

3m saved
Insight
Article

FAQ

Why Bullish?

The VenoValve's cost-effectiveness could lead to increased adoption and revenue, similar to successful medical device launches that drove significant stock price increases.

How important is it?

The VenoValve's potential to save substantial costs directly impacts NVNO's market prospects, making it highly relevant for investors and stakeholders.

Why Long Term?

As the treatment gains traction, ongoing demand and cost savings may improve NVNO's market position over time, reflecting historical trends in innovative healthcare solutions.

Related Companies

MDTBSXABT
Clinical data and cost-effectiveness analysis demonstrates the VenoValve would provide both better health outcomes and lower costs compared to current standard of care treatments The VenoValve could potentially save $5.9 billion annually in healthcare costs for the approximately 2.5 million U.S. patients with severe CVI Company to host live webcast with lead author of the cost-analysis manuscript, today, August 6th, at 12:00 PM ET; Access the Webcast Here IRVINE, CA / ACCESS Newswire / August 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announcedpreliminary findings from a VenoValve health economic study, which indicate that the VenoValve would be a cost-effective treatment option for patients with severe Chronic Venous Insufficiency (CVI) caused by deep valvular incompetency. The Company announced it will host a live webcast to discuss the cost-effectiveness analysis results today, Wednesday, August 6th at 12:00 PM ET (details below).

Related News